Beyond Medicine is a digital healthcare company dedicated to transforming the management and treatment of chronic conditions through AI-powered Digital Therapeutics (DTx).

Our flagship product, Clickless DTx, is a prescription digital therapeutic designed for the treatment of temporomandibular disorder (TMD). By integrating video-based motion recognition technology with cognitive behavioral therapy (CBT), Clickless DTx delivers personalized treatment programs tailored to each patient. It enables continuous care beyond the clinic by leveraging real-world behavioral data and providing clinicians with actionable insights through an integrated dashboard.

Beyond Medicine has successfully conducted the world’s first randomized controlled trial (RCT) for a TMD digital therapeutic, with results published in an SCI-indexed journal. The company has also been recognized as an Innovative Medical Device by the Korean Ministry of Food and Drug Safety (MFDS) and has obtained regulatory approval as a Software as a Medical Device (SaMD).

Moving forward, Beyond Medicine aims to expand into global markets including the United States, Japan, and Europe through regulatory pathways such as FDA and CE approvals. The company is also extending its pipeline into new therapeutic areas, including facial paralysis rehabilitation, to broaden the impact of its digital therapeutics platform.